Merck (MRK) vs. Novartis (NVS)

Company Profile

Merck (MRK) and Novartis (NVS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Merck (MRK) trades as a standard ordinary-equity line, while Novartis (NVS) is an ADR tied to a foreign-share or depositary-receipt structure — compare with FX exposure, program fees, and dividend-withholding-tax differences in mind.

Historical Performance

Historical Performance at a Glance

Profitability

Both Merck (MRK) at 17.93% and Novartis (NVS) at 31.67% rank in the top quartile for Return on Equity (TTM) among industry peers, indicating strong returns on shareholders’ equity.

Novartis (NVS) at 24.06% ranks in the top quartile for Net Profit Margin (TTM), ahead of Merck (MRK) at 13.59%, which sits closer to the industry mid-range.

Both Merck (MRK) at 18.18% and Novartis (NVS) at 30.37% rank in the top quartile for Operating Profit Margin (TTM) among industry peers, indicating both companies convert revenue into operating income more strongly than typical competitors.

Profitability at a Glance

Financial Strength

Both Merck (MRK) at 1.30 and Novartis (NVS) at 0.85 run Current Ratio (MRQ) in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Merck (MRK) at 1.07 and Novartis (NVS) at 1.22 run Debt-to-Equity Ratio (MRQ) in the higher-leverage quartile of industry peers, indicating more debt relative to equity than typical competitors.

Both Merck (MRK) at 22.74 and Novartis (NVS) at 15.76 rank in the top quartile for Interest Coverage Ratio (TTM) among industry peers, indicating ample headroom to cover interest payments from operating income or EBIT.

Financial Strength at a Glance

Growth

Revenue Growth

Revenue Growth at a Glance

EPS Growth

EPS Growth at a Glance

Dividend

Both Merck (MRK) at 2.90% and Novartis (NVS) at 3.19% report Dividend Yield (TTM) near their industry mid-ranges, so neither company stands out strongly from peers on cash yield relative to share price.

Novartis (NVS) reports an unusual Dividend Payout Ratio (TTM) of 120.63% — outside the typical 0–100% range, indicating either negative earnings (negative ratio) or dividends above current-period earnings (above 100%), both signaling sustainability concerns. Meanwhile Merck (MRK) reports 44.79%, ranking against industry peers normally.

Dividend at a Glance

Valuation

Both Merck (MRK) at 31.74 and Novartis (NVS) at 20.09 post Price-to-Earnings Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing earnings multiple.

Both Merck (MRK) at 4.31 and Novartis (NVS) at 4.83 post Price-to-Sales Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing revenue multiple.

Both Merck (MRK) at 6.48 and Novartis (NVS) at 8.12 post Price-to-Book Ratio (MRQ) near the typical industry midpoint — neither company stands out strongly from peers on book-value multiple.

Valuation at a Glance